Clinical Trials on Cardiometabolic Risk Factors in Portugal

Total 27 results

Escola Superior de Tecnologia da Saúde do Porto

Completed

Effect of Aerobic Exercise Associated With Abdominal Radiofrequency on on Adipose Tissue in Women:

Cardiovascular Risk Factor | Metabolic Disease

Portugal
Escola Superior de Tecnologia da Saúde do Porto

Completed

Effects of Shockwave Therapy Versus Radiofrequency

Cardiovascular Risk Factor | Metabolic Disease | Photoaging

Portugal
Faculdade de Motricidade Humana

Completed

Lifestyle Intervention in Overweight Women (PESO)

Obesity | Physical Activity | Weight Loss | Cardiovascular Risk Factor | Behavior, Health | Nutritional and Metabolic Disease | Lifestyle, Sedentary

Portugal
Universidade Católica Portuguesa
Associação para o Desenvolvimento do Centro Académico de Investigação e Formação...

Active, not recruiting

Impact of a Mediterranean Diet on Cardiovascular Disease Risk Factors (RATE)

Cardiovascular Disease Risk

Portugal
University of Évora
São João de Deus School of Nursing; Horizon 2020 - Portugal 2020 (ALT20-03-0145-FEDER-000007...

Completed

Multimodal Exercise Programs for Fall Prevention: A Randomized Controlled Trial

Fallers | High Risk of Falling

Portugal
Technical University of Lisbon

Completed

What is in Fact the Contribution of Reducing Time Spent in Sedentary Behaviors on Daily Energy Expenditure? A Doubly Labeled Water Study

Risk Reduction Behavior

Portugal
Aveiro University
Centro de Saúde de Anadia

Completed

Physical Condition and Self-efficacy in People With Fall Risk (Fall Risk)

Fall Risk

Portugal
University of Coimbra
Fundação para a Ciência e a Tecnologia

Recruiting

Validation of the REMINDER Dementia Risk Reduction Program (REMINDER)

Healthy Aging | Risk Reduction | Old Age; Dementia

Portugal
University of Évora

Completed

Graphomotor Intervention Program for Handwriting Difficulties Prevention in Preschool Age

Typical Development | Risk of Dysgraphia | Dysgraphia

Portugal
University of Évora

Completed

Graphomotor Intervention Program for Handwriting Difficulties Prevention in School-Age

Typical Development | Risk of Dysgraphia | Dysgraphia

Portugal
José Cunha-Vaz

Completed

Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

High Risk Proliferative Diabetic Retinopathy

Portugal
Association for Innovation and Biomedical Research...

Completed

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

Diabetes Mellitus Type II | Diabetes Mellitus Type I | High Risk Proliferative Diabetic Retinopathy

Portugal
Association for Innovation and Biomedical Research...
European Vision Institute Clinical Research Network

Completed

Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (PROTEUS)

High Risk Proliferative Diabetic Retinopathy

Portugal, Italy, United Kingdom, France
Clinical Hospital Centre Zagreb
European Society of Hypertension

Unknown

Blood Pressure Control in ESH Excellence Centres (BP-CON)

White Coat Hypertension | Blood Pressure | Lifestyle Risk Reduction

Israel, Greece, Belgium, Germany, Armenia, Austria, Bulgaria, Croatia, Czechia, Estonia, Italy, Lebanon, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, Spain, Sweden, Ukraine, United Kingdom
PedNet Haemophilia Research Foundation
Lund University Hospital

Recruiting

The European Paediatric Network for Haemophilia Management ( PedNet Registry) (PedNet)

Factor IX Deficiency | Factor VIII Deficiency

Norway, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
Sanofi
Bristol-Myers Squibb

Completed

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Argentina, Denmark, Finland, Hungary, Norway, United... and more
Sanofi
Bristol-Myers Squibb

Terminated

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Russian Federation, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Denmark, Finland, H... and more
European Organisation for Research and Treatment...

Active, not recruiting

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION)

Malignant Neoplasm of Stomach | Malignant Neoplasm of Cardio-esophageal Junction of Stomach | Epidermal Growth Factor Receptor (EGFR) Protein Overexpression

Spain, Korea, Republic of, Singapore, Switzerland, Germany, United Kingdom, Italy, France, Estonia, Belgium, Netherlands, Norway, Portugal
Boston Scientific Corporation

Completed

Registry on WATCHMAN Outcomes in Real-Life Utilization (EWOLUTION)

Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke

Ireland, Spain, Germany, Netherlands, France, United Kingdom, Italy, Russian Federation, Portugal, Belgium, Poland, Saudi Arabia, United Arab Emirates
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Italy, Finland and more
Kite, A Gilead Company

Recruiting

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)

High-risk Large B-cell Lymphoma (LBCL)

United States, Austria, Spain, Italy, Australia, Germany, Netherlands, Canada, Portugal, United Kingdom, France
Bayer

Active, not recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (OASIS-4)

Hot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Spain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
Bayer

Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic Attack

United States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, France, Slovakia, Austria, Czechi... and more
Novo Nordisk A/S

Recruiting

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)

Inflammation | Chronic Kidney Disease | Cardiovascular Risk

Korea, Republic of, Spain, China, Taiwan, Mexico, Netherlands, Latvia, Malaysia, United States, Thailand, Hungary, Australia, Poland, South Africa, India, Portugal, Romania, United Kingdom, Brazil, Sweden, Italy, Lithuania, Japan, Serbia and more
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more

Clinical Trials on Cardiometabolic Risk Factors in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations